DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Effect of Methylprednisolone on Orthostatic Intolerance and Heart Rate Variability in Hip-arthroplasty Patients

Information source: Rigshospitalet, Denmark
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Osteoarthrosis

Intervention: Methylprednisolone (Drug); Isotonic Sodium Chloride (Drug)

Phase: Phase 2/Phase 3

Status: Not yet recruiting

Sponsored by: Rigshospitalet, Denmark

Official(s) and/or principal investigator(s):
Viktoria Lindberg-Larsen, MD, Principal Investigator, Affiliation: Section for Surgical Pathophysiology, Rigshospitalet

Overall contact:
Henrik Kehlet, Professor, Phone: 0045 35454074, Email: henrik.kehlet@regionh.dk

Summary

The study evaluates the pathophysiological effects of a single dose Methylprednisolone administered prior to total hip-arthroplasty (THA) surgery. The investigators examine the effect on orthostatic intolerance, orthostatic hypotension and heart rate variability (HRV) to evaluate the efficacy of Methylprednisolone regarding blood pressure regulation and autonomic responses after THA. Half of participants will receive intravenous Solu-Medrol 125 mg, while the other half will receive placebo. The investigators hypothesize that the group receiving Methylprednisolone will be less orthostatic intolerant, experience less orthostatic hypotension and have an improved autonomic response compared to the placebo-group, early after THA.

Clinical Details

Official title: Effect of Preoperative Intravenous High Dose Methylprednisolone on Orthostatic Intolerance and Heart Rate Variability in Patients Scheduled for Total Hip-arthroplasty

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)

Primary outcome: Difference in incidence of orthostatic intolerance from baseline to 6 hours after surgery

Secondary outcome:

Difference in incidence of orthostatic intolerance from baseline to 24 hours after surgery

Change in non-invasive blood pressure from baseline to 24 hours after surgery

Change in heart rate variability from baseline to 24 hours after surgery

Change in stroke volume and cardiac output from baseline to 24 hours after surgery

Change in systemic vascular resistance from baseline to 24 hours after surgery

Change in pain intensity from baseline to 24 hours after surgery

Change in concentration of plasma-hemoglobin from baseline to 48 hours after surgery

Change in concentration of C-reactive protein from baseline to 48 hours after surgery

Detailed description: The anti-inflammatory effects of glucocorticoids are well known. The beneficial effects in postoperative pain, postoperative nausea and vomiting are well-documented. Hip-arthroplasty surgery and the inflammatory stress response in general affect the potential of recovery. Early postoperative orthostatic intolerance is common in patients undergoing THA with an incidence of 40%. The mechanism is thought related to an impaired autonomic regulation caused by surgery-induced inflammation. The effect of glucocorticoids on orthostatic intolerance, orthostatic hypotension and HRV after hip-arthroplasty surgery is unknown and calls for further investigation. The study is to be considered as exploratory. The primary analysis of the primary outcome measure is a comparison of the incidence of orthostatic intolerance from baseline to 6 hours postoperatively between the two groups. For calculation of sample size the difference in incidence between groups (40% versus 10%) from baseline (before surgery) to 6 hours after THA-surgery, a risk of type I errors 5% and a risk of type II errors 20% (80% power) were used. The primary analysis is carried out on all included patients (intention-to-treat) with baseline values as covariate. Secondary exploratory per-protocol analysis might be performed. Missing outcomes will be analysed using multiple imputation due to expected strong time trends. The secondary outcomes measures; Non-invasive blood pressure, systemic vascular resistance, cardiac output, HRV, plasma-hemoglobin, C-reactive protein. For further details please also view the European Clinical Trials Database (EudraCT) registration: EudraCT nr.: 2015-000102-19

Eligibility

Minimum age: 55 Years. Maximum age: 80 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Osteoarthrosis

- Undergoing total unilateral hip-arthroplasty surgery

- Speak and understand Danish

- Have given informed content

Exclusion Criteria:

- Revision or bilateral hip-arthroplasty surgery

- General anaesthesia

- Allergy or intolerance towards Methylprednisolone

- Local or systemic infection

- Permanent systemic treatment with steroids within 30 days peroperatively

- Insulin-dependent diabetes

- Atrial fibrillation

- Neurological disease incl. Parkinsons

- Daily use of hypnotics or sedatives

- Alcohol abuse >35 units per week

- Active treatment of ulcer within 3 months preoperatively

- Cancer disease

- Autoimmune disease incl. rheumatoid arthritis

- Pregnant or breast feeding women

- Menopause <1 year

Locations and Contacts

Henrik Kehlet, Professor, Phone: 0045 35454074, Email: henrik.kehlet@regionh.dk

Copenhagen University Hospital, Bispebjerg, Copenhagen NV 2400, Denmark; Not yet recruiting
Torben Beck, MD, Phone: 0045 21299671, Email: torben.beck@regionh.dk
Additional Information

Related publications:

Husted H. Fast-track hip and knee arthroplasty: clinical and organizational aspects. Acta Orthop Suppl. 2012 Oct;83(346):1-39. doi: 10.3109/17453674.2012.700593. Review.

Kehlet H. Fast-track hip and knee arthroplasty. Lancet. 2013 May 11;381(9878):1600-2. doi: 10.1016/S0140-6736(13)61003-X.

Grubb BP. Neurocardiogenic syncope and related disorders of orthostatic intolerance. Circulation. 2005 Jun 7;111(22):2997-3006. Review.

Bundgaard-Nielsen M, Jans Ø, Müller RG, Korshin A, Ruhnau B, Bie P, Secher NH, Kehlet H. Does goal-directed fluid therapy affect postoperative orthostatic intolerance?: A randomized trial. Anesthesiology. 2013 Oct;119(4):813-23. doi: 10.1097/ALN.0b013e31829ce4ea.

Bundgaard-Nielsen M, Jørgensen CC, Jørgensen TB, Ruhnau B, Secher NH, Kehlet H. Orthostatic intolerance and the cardiovascular response to early postoperative mobilization. Br J Anaesth. 2009 Jun;102(6):756-62. doi: 10.1093/bja/aep083. Epub 2009 Apr 27.

Starting date: September 2015
Last updated: May 14, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017